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ABSTRACT
Studies measuring psychological distress in individuals
with cystic ﬁbrosis (CF) have found high rates of both
depression and anxiety. Psychological symptoms in both
individuals with CF and parent caregivers have been
associated with decreased lung function, lower body
mass index, worse adherence, worse health-related
quality of life, more frequent hospitalisations and
increased healthcare costs. To identify and treat
depression and anxiety in CF, the CF Foundation and the
European CF Society invited a panel of experts, including
physicians, psychologists, psychiatrists, nurses, social
workers, a pharmacist, parents and an individual with
CF, to develop consensus recommendations for clinical
care. Over 18 months, this 22-member committee was
divided into four workgroups: Screening; Psychological
Interventions; Pharmacological Treatments and
Implementation and Future Research, and used the
Population, Intervention, Comparison, Outcome
methodology to develop questions for literature search
and review. Searches were conducted in PubMed,
PsychINFO, ScienceDirect, Google Scholar, Psychiatry
online and ABDATA by a methodologist at Dartmouth.
The committee reviewed 344 articles, drafted statements
and set an 80% acceptance for each recommendation
statement as a consensus threshold prior to an
anonymous voting process. Fifteen guideline
recommendation statements for screening and treatment
of depression and anxiety in individuals with CF and
parent caregivers were ﬁnalised by vote. As these
recommendations are implemented in CF centres
internationally, the process of dissemination,
implementation and resource provision should be closely
monitored to assess barriers and concerns, validity and
use.
INTRODUCTION
Original studies, meta-analyses and systematic
reviews have shown that adults and children with
chronic conditions, as well as parent caregivers, are
at higher risk for depression and anxiety in com-
parison with community samples1 2 (see online sup-
plementary appendix A). Cystic ﬁbrosis (CF), a
common genetic, life-shortening chronic illness,
leading to frequent infections and progressive
failure of most organ systems (eg, lungs, pancreas)
was the focus of our study.3 Despite recent
advances in diagnosis and treatment, management
of CF requires a complex, time-consuming daily
regimen taking 2–4 h/day.4 Thus, CF continues to
be one of the most difﬁcult chronic conditions to
manage.
There is strong consensus that depression is
deﬁned as “a mood disorder that affects the way a
person feels, thinks or behaves, which impairs
social or occupational functioning” (ref., 5 p.775).
Central to this is depressed mood or loss of interest
in most activities.6 Risk for suicide is a core compo-
nent of depression, is a major cause of death
among adolescents and adults in the general popu-
lation and in recent Cystic Fibrosis Foundation
(CFF) Registry data, 1.6% of deaths were
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Key messages
What is the key question?
▸ Given the high prevalence of depression and
anxiety among individuals with cystic ﬁbrosis
(CF) and parent caregivers, the International
Committee on Mental Health in CF (ICMH)
tackled the question of how we can change
clinical practice to improve mental health
outcomes.
What is the bottom line?
▸ The ICMH is recommending that when annual
screening shows elevated levels of depression
and anxiety, clinical diagnostic procedures
should be implemented, followed by
evidence-based psychological and/or
pharmacological interventions, if needed.
Why read on?
▸ International implementation of the guidelines,
which were developed over nearly 3 years by a
number of international experts, will address
the needs of individuals with CF and parent
caregivers, and will likely improve their health
outcomes and quality of life.
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categorised as explicit suicide.7 Anxiety is a “state of intense
apprehension, uncertainty, and fear resulting from the anticipa-
tion of a threatening event or situation to the degree that
normal physical and psychological functioning is disrupted.” 8
Procedural anxiety, which is particularly important for indivi-
duals with CF, has been deﬁned as an acute and excessive fear
of a medical or surgical procedure that results in acute stress or
avoidance. Patients may experience anxiety in anticipation of or
during procedures. Avoidance due to procedural anxiety can
have negative health consequences.9
Studies measuring psychological distress in individuals with
CF have found high rates of both depression and anxiety. The
prevalence of depression ranges from 8% to 29% among chil-
dren and adolescents, and 13–33% among adults;10 11 anxiety
in adults has ranged from 30% to 33%.7 Caregivers have also
reported elevations in depression scores ranging from 20% to
35%.12 A recent study in nine countries screened 6088 patients
with CF ages 12 years through adulthood and 4102 parents.13
Elevated symptoms of depression were found in 130 adolescents
(10%), 913 adults (19%), 1165 mothers (37%), and 305 fathers
(31%). Anxiety was reported by 281 adolescents (22%), 1503
adults (32%), 1496 mothers (48%), and 343 fathers (36%).
Elevations were 2–3 times those reported in community
samples. High rates of comorbidity were found between depres-
sion and anxiety symptoms across patient and parent samples.
Further, among 1122 parent–teen dyads, adolescents were more
than twice as likely to report elevated depression or anxiety if
either parent was elevated.
Importantly, psychological symptoms in both patients and
parents have been associated with decreased lung function,14
lower body mass index,15 worse adherence,10 16 worse
health-related quality of life,17 more frequent hospitalisations and
increased healthcare costs15 (see online supplementary appendix
B). Given these high rates of depression and anxiety and their
effects on quality of life and key health outcomes, the CFF and the
European Cystic Fibrosis Society (ECFS) supported the formation
of an International Committee onMental Health in CF (ICMH).
METHODS
The CFF and ECFS formed a 22-member multidisciplinary
committee including professionals, parents of individuals with
CF and an adult with CF by invitation. They met in May 2013
and elected to focus on the assessment and treatment of depres-
sion and anxiety. Four workgroups were created: Screening;
Psychological Interventions; Pharmacological Treatments and
Implementation and Future Research. Each workgroup devel-
oped topic-speciﬁc questions using the Population, Intervention,
Comparison, Outcome (PICO) format.18 These questions were
reviewed and approved by the entire committee before literature
searches were conducted.
The PICO questions were used to guide literature searches in
PubMed, PsychINFO, ScienceDirect, Google Scholar, Psychiatry
online and ABDATA conducted by a methodologist at the
Dartmouth Institute of Health Policy and Clinical Practice at the
Geisel School of Medicine at Dartmouth. Searches were limited
to the English language and the period of 1960–2015. Standard
textbooks were also consulted. Additional topic-relevant guide-
lines and reviews targeting general, chronically ill and
CF-speciﬁc populations were identiﬁed through searches of the
websites of organisations, including American Thoracic Society,
Cochrane Collaboration, American Academy of Pediatrics,
Agency for Healthcare Research and Quality, National Health
and Medical Research Council, Canadian Psychiatric
Association, National Institute for Health Care Excellence,
American Academy of Child and Adolescent Psychiatry,
American Psychiatric Association, British Association for
Psychopharmacology, World Federation of Societies of
Biological Psychiatry and US Department of Veterans Affairs.
In April 2014, the committee reconvened to ﬁnalise the rec-
ommendation statements. A threshold consensus vote of 80%
acceptance for each statement was set prior to the meeting. At
the meeting, each workgroup presented draft recommendation
statements and rationale to the full committee. After review and
discussion of each statement, committee members voted
anonymously. Review and voting continued until the 80% or
higher acceptance rate was reached for each statement.
A preliminary version of the manuscript was distributed for
public comment to the CF clinical, parent and patient communi-
ties in Europe and the USA. Feedback and comments were col-
lected via a web-based survey. The committee reviewed and
responded to this feedback.
RESULTS
A total of 21 756 references were retrieved in the creation of
these recommendation statements. Of those, 980 abstracts and
books were reviewed, and 344 articles were chosen for more
in-depth review. Articles were excluded if they focused on chil-
dren under the age of 7 because there is less evidence support-
ing screening and treatment of depression and anxiety in this
age group. However, attention to the mental health of families
from the time of diagnosis is recommended by other guide-
lines19 and in this review, we included articles on parents of
children with CF from birth to adulthood. After review, key arti-
cles were selected to address the PICO questions under consid-
eration by the committee. Articles not referenced in this
document appear in the online supplementary appendices.
Fifteen guideline recommendation statements for screening and
treatment of depression and anxiety in individuals with CF and
parent caregivers were ﬁnalised by vote (table 1).
PREVENTION
In the course of routine care, all individuals with CF and care-
givers should be offered education and preventative, supportive
interventions to promote effective coping skills and disease
management. Care teams should provide support in a sensitive
and empathic manner, paying attention to individual and family
functioning, encouraging habits that promote good physical and
mental health—including CF centres that are already using pre-
ventive interventions every day from the time of ﬁrst diagnosis
through the end of life, in the form of providing education
about CF in a sensitive and empathetic manner, paying attention
to individual and family functioning and coping and encour-
aging habits that promote good physical and mental health—
including exercise, good nutrition, sleep hygiene and ﬁnding
ways to balance the demands of CF with education, work and
pleasurable activities that make life satisfying and meaningful.20
Speciﬁc preventive strategies may be developed to reduce the
risk of anxiety and depression in CF. For example, training
in speciﬁc problem-solving and cognitive behavioural skills
can decrease anxiety and improve resilience9 21 See
Recommendation 1 in table 1.
In addition, there are a number of painful medical procedures
experienced by patients with CF, including blood draws and intra-
venous or peripherally inserted central catheter insertions, and
behavioural approaches can reduce distress related to these proce-
dures.9 For individuals with CF undergoing medical procedures,
the ICMH recommends that behavioural approaches be used to
reduce the risk of distress. See Recommendation 2 in table 1.
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SCREENING
Care pathways and provision of high-quality care for depres-
sion/anxiety should be in place prior to implementation of a
screening programme.22 Given that models of healthcare deliv-
ery and availability of resources differ worldwide, it is difﬁcult
to specify the qualiﬁcations and training of the team member
who will assess and treat mental health issues.22 In Europe, CF
teams can consult the ECFS Standards of Care documents,20
but in the USA this document does not exist and the designated
professional may be a social worker, nurse practitioner, psych-
ologist or psychiatrist. Before initiating annual screening,
CF Teams should (1) identify a clinician with specialised expert-
ise and training in mental health (e.g., licensed social worker,
psychologist, psychiatrist), (2) develop educational materials on
the importance of assessing and treating depression and anxiety
and (3) develop a list of referral sources within the hospital and
surrounding community. A plan to address suicidal ideation,
which can be associated with depression, should also be estab-
lished (eg, clinical assessment or interview, visit to emergency
department). See online supplementary appendix C for a
Manual of Procedures and Toolkit for Implementation.
Evidence from The International Depression Epidemiological
Study (TIDES) indicated that when a parent reported elevated
depressive or anxious symptoms, the adolescent with CF was
more than twice as likely to also experience depression and
anxiety.13 There is limited guidance on routine screening of
younger children below age 12. Thus, for children with CF,
ages 7–11, whose parents score in the elevated range or who
themselves have clinical concerns, referrals for screening or
clinical assessment for these younger children should be made
to mental health experts in the CF team, in the hospital or in
the community. See Recommendation 3 in table 1.
The US Screening Guidelines recommend universal screening
for depression in adolescents and adults and the UK
Table 1 Consensus statements
Recommendation statement
Consensus
(%)
Prevention
1. For all individuals with CF and caregivers, the CFF/ECFS International Committee on Mental Health in CF (ICMH) recommends that ongoing education
and preventative, supportive interventions, such as training in stress management and the development of coping skills, aligned with appropriate
developmental stage and disease events be offered.
100
2. For all individuals with CF undergoing medical procedures, the ICMH recommends that behavioural approaches be used to reduce the risk of distress. 100
Screening
3. The ICMH recommends that children with CF ages 7–11 be clinically evaluated for depression and anxiety when caregiver depression or anxiety scores
are elevated, or when significant symptoms of depression or anxiety in the child are reported or observed by patients, caregivers or members of the CF
multidisciplinary team.
100
4. The ICMH recommends annual screening for depression and anxiety with the PHQ-9 and GAD-7 for adolescents and adults with CF (ages 12–
adulthood).
100
5. The ICMH recommends offering annual screening for depression and anxiety to at least one primary caregiver of children and adolescents with CF (ages
0–17) using one of the following approaches listed below, depending on staffing and resources:
▸ Screening with the PHQ-9 and GAD-7
▸ Screening with the PHQ-8 and GAD-7
▸ Screening with the PHQ-2 and GAD-2
100
Clinical Assessment
6. The ICMH recommends that any treatment for depression and anxiety in individuals with CF and caregivers be based on clinical diagnosis.
▸ A healthcare provider with appropriate training and expertise should evaluate the clinical significance of elevated screening scores and presenting
symptoms to perform a differential diagnosis before initiating treatment.
100
7. For caregivers of individuals with CF who have clinically significant symptoms of depression/anxiety, the ICMH recommends referral for treatment to
primary care or mental health services after initial assessment with the CF team.
100
Intervention
8. For all individuals with CF and symptoms of depression/anxiety, the ICMH recommends a flexible, stepped care model of clinical intervention developed
and implemented in close collaboration with patients and caregivers, the multidisciplinary CF team and other treatment providers or consultants, such as
primary care or mental health specialists.
▸ CF teams must identify who will be responsible to initiate and coordinate care and monitor treatment effects.
100
9. The ICMH recommends that in children with CF ages 7–11, who have clinically significant depression or anxiety, evidence-based psychological
interventions are recommended as the first-line treatment.
100
10. For individuals with CF ages 12–adulthood and mild depression or anxiety symptoms, the ICMH recommends education about depression/anxiety,
preventative or supportive interventions and rescreening at the next clinic visit.
100
11. For individuals with CF ages 12–adulthood and moderate depression or anxiety, the ICMH recommends offering or providing a referral for
evidence-based psychological interventions, including CBT or IPT.
▸ When psychological intervention is unavailable, declined or not fully effective, antidepressant treatment should be considered.
100
12. For individuals with CF ages 12–adulthood and severe depression, the ICMH recommends use of combined evidence-based psychological interventions
and antidepressant pharmacotherapy.
100
13. For individuals with CF ages 12–adulthood and severe anxiety, the ICMH recommends offering exposure-based CBT.
▸ When exposure-based CBT is unavailable, declined or not fully effective, antidepressant medications can be considered.
100
14. The ICMH recommends that the SSRIs citalopram, escitalopram, sertraline and fluoxetine are appropriate first-line antidepressants for most individuals
with CF, ages 12–adulthood, requiring pharmacotherapy.
▸ In selecting an antidepressant and adjusting its dosage, close monitoring of therapeutic effects, adverse effects, drug–drug interactions and medical
comorbidities is recommended.
100
15. The ICMH recommends that lorazepam be considered for short-term use in individuals with CF with moderate-to-severe anxiety symptoms, associated
with medical procedures, who have not responded to behavioural approaches.
100
CBT, cognitive behavioural therapy; CF, cystic fibrosis; CFF, Cystic Fibrosis Foundation; ECFS, European Cystic Fibrosis Society; GAD, Generalised Anxiety Disorder Questionnaire; IPT,
interpersonal therapy; PHQ, Patient Health Questionnaire; SSRIs, selective serotonin reuptake inhibitors.
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recommends screening for high-risk populations.6 5 23–26 In
addition, chronic disease practice guidelines9 recommend
mental health screening because of their link to worse health
outcomes. These practice guidelines, in combination with recent
screening evidence in CF,13 support our recommendation for
annual screening of depression and anxiety in patients with CF
ages 12 years and older and parent caregivers of children with
CF aged from birth to 17 years of age.
Internationally, more than 48 different screening tools were
in use at CF centres.22 To standardise the screening process
using reliable, valid measures that yield clinically relevant scores,
the committee recommends the use of the Patient Health
Questionnaire 9 (PHQ-9), which includes an item to assess
suicide risk, and Generalised Anxiety Disorder 7-item (GAD-7)
Scale for annual screening of adolescents (ages 12 years and
older) and adults with CF and offered annually to at least one
primary caregiver of children with CF (ages 0–17 years). The
PHQ-9 and GAD-7 are free, brief, reliable and valid, with
optimal cut-off scores for detecting psychological symptoms,
map onto current diagnostic criteria Diagnostic and Statistical
Manual of Mental Disorders, 5th Edition (DSM-5))8 and are
available in all major languages.
Guidelines from US and UK societies advocate for the use of
PHQ-9 when appropriate diagnostic, treatment and follow-up
services are available.6 24 25 27 The PHQ-9 is also recommended
for depression severity assessment.8 When screening anxiety, UK
societies endorse the use of the GAD-7.28 Figure 1 outlines the
meta-strategy for screening and treating depression and anxiety.
A brief explanation and discussion of the rationale for screen-
ing mental health issues is recommended for all patients and
parent caregivers, followed by administration of the PHQ-9 and
GAD-7 (http://www.phqscreeners.com/). For caregivers, centres
that do not have the resources or expertise to assess suicidality
may choose to omit the question on the PHQ-9 that assesses
self-harm and administer the PHQ-8. An alternative approach is
to use two items from the PHQ-9 on low mood and anhedonia
(PHQ-2, http://www.cqaimh.org/pdf/tool_phq2.pdf) and two
items from the GAD-7 on feeling anxious/nervous and not
being able to stop or control worrying (GAD-2, http://
depression.acponline.org/content/all/tools/dcg_o11.pdf). See
Recommendations 4 and 5 in table 1.
CLINICAL ASSESSMENT
We recommend that a mental health specialist (eg, a licensed
social worker, psychologist, psychiatrist) perform the screening.
However, there may be other providers (eg, nurse, physician),
with additional training or consultation, who can conduct the
screening. Individuals with CF who screen positive for depres-
sion/anxiety must have a clinical assessment prior to initiation of
or referral for treatment to identify the presence, duration and
severity of these symptoms, as well as prior history and risk
factors. Severity of CF, prior history of depression or anxiety,
previous treatment and response to treatment(s), family history
of psychiatric illnesses, comorbid psychiatric diagnoses and the
presence of other chronic illnesses should be assessed.
Treatment decisions should be based on clinical diagnosis and
not solely on the screening results. CF healthcare professionals
should decide when referral to a trained mental health profes-
sional is required.
All caregivers who screen positive and have clinically signiﬁ-
cant symptoms of depression/anxiety should be advised to
follow up with their primary care provider or mental health ser-
vices (outside the CF centre), with provision of referrals as
needed. Although some CF centres may have the expertise and
resources to treat parental depression and anxiety within their
centre, this will not be the case in a majority of countries. Thus,
we are recommending provision of psychological services for
parents outside the CF team.
For patients or caregivers who screen positive for suicide risk
(Question 9 on the PHQ-9), the designated mental health
expert in the CF team should follow up immediately to deter-
mine the severity. This should include a clinical interview or
further assessment. There are formal tools, such as the
Columbia Suicide Severity Rating Scale (C-SSRS; http:/www.
ccrs.columbia.edu/ecssrs.hmtl), which can also be used to evalu-
ate this risk. This measure is free, well validated and available in
over 100 languages. This tool was designed for use by ‘lay pro-
fessionals’ (eg, teacher, law enforcement) and has an on-line
training course and certiﬁcation available. It is appropriate for
children, adolescents and adults.29 See Recommendations 6 and
7 in table 1.
INTERVENTION
A variety of international authorities and professional associa-
tions have issued evidence-based guidelines for the treatment of
depression and anxiety in the general population and in those
with chronic illness (see online supplementary appendix D
tables 1 and 2). Given that minimal research has speciﬁcally
examined the treatment of depression and anxiety in CF,30 the
ICMH used developmentally appropriate, existing guidelines to
frame CF-speciﬁc recommendations. Although treatment plans
should consider potential adverse effects and overall burden of
care, the risks of not treating depression or anxiety are often
heightened in individuals with CF leading to worse adherence
to CF treatments and increased healthcare utilisation and
costs.10 15 17
Treatment plans for depression/anxiety must be developed
and implemented in close collaboration with patients and care-
givers, the multidisciplinary CF healthcare professionals and
other providers, such as primary care or mental health specia-
lists. Figures 2 and 3 illustrate a ﬂexible stepped care model for
prevention, screening and intervention for individuals with CF
and caregivers. Factors such as patient age, screening scores,
clinical assessment, functional impairment and safety should be
considered in developing a treatment plan. In addition, interven-
tions should be adjusted to account for patient/caregiver prefer-
ences, medical status, psychiatric comorbidities, treatment
history, resource availability, access to treatments and local prac-
tice patterns. See Recommendation 8 in table 1.
The PHQ-9 and GAD-7 can be used both to screen these
symptoms and to assess and monitor treatment response and
adequacy of the treatment plan. If depression or anxiety symp-
toms continue to be elevated or functioning remains impaired
12 weeks later, additional or alternative interventions should be
offered until symptoms return to within normal range.
Depending on the clinical context, the differential diagnosis
in individuals with symptoms of depression and anxiety may
include bipolar disorder, post-traumatic stress disorder, delir-
ium, substance abuse or disease-related factors, such as fatigue,
sleep disturbance, dyspnoea, pain31 and vitamin D deﬁciency.32
Concomitant CF symptoms should be actively treated while
depression and anxiety are being addressed. CF pulmonary
exacerbations may worsen depression and anxiety through mul-
tiple biopsychosocial mechanisms, including the adverse impact
of demoralisation, stress and inﬂammation.33
Considering the limited evidence for psychopharmacological
treatment of depression and anxiety in children, psychological
interventions tailored to individual and family needs are
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recommended as the ﬁrst-line approach in all children with CF
ages 7–11 who require treatment. Specialised consultation
should be obtained if psychological interventions are not sufﬁ-
ciently effective. See Recommendation 9 in table 1.
Psychological interventions
Adolescents and adults with CF (ages 12 and above) whose
depression or anxiety is in the mild range should receive educa-
tion, preventive or supportive psychological interventions and
rescreening at the next CF visit. Evidence-based psychological
interventions should be offered to all adolescents and adults
with CF whose depression or anxiety is of at least moderate
severity. An extensive body of literature supports the efﬁcacy
and effectiveness of cognitive behavioural therapy (CBT) for the
treatment of both depression and anxiety, whereas some evi-
dence indicates that interpersonal therapy (IPT) is an effective
treatment for depression (see online supplementary appendix D
tables 1–3).6 CBT is a psychotherapeutic approach that
addresses dysfunctional emotions, behaviours and cognitions. It
combines cognitive interventions (ie, challenge and replace
negative thoughts with more functional cognitions) with the
principles of behaviour modiﬁcation (eg, training of skills and
behaviours, using classical and operant learning principles).34
See Recommendations 10 and 11 in table 1.
Education and cognitive restructuring are included in CBT
interventions for both depression and anxiety, whereas behav-
ioural activation (eg, engaging in pleasant activities) is an
additional core ingredient of most CBT manuals for the treat-
ment of depression. Relaxation training and gradual exposure to
triggers of anxiety are considered essential components of
anxiety-speciﬁc CBT. IPT is a short-term treatment that
encourages patients to regain control of mood and functioning.
It is based on a treatment alliance in which the therapist
empathically engages the patient, helps the patient feel under-
stood and structures success experiences.35 Comparisons of
CBT and IPT suggest there is broader empirical support, dissem-
ination and training and worldwide adoption of CBT versus
IPT. CBT has also demonstrated efﬁcacy in treating comorbid
depression and anxiety, which occur commonly among those
with CF.13
Pharmacological interventions
In individuals with CF, antidepressant medication should gener-
ally be prescribed in conjunction with psychological interven-
tions, as part of a comprehensive treatment plan. For those with
severe depression, evidence supports the combined use of anti-
depressants and psychological interventions as the most effective
initial therapy.36 For adolescents and adults with CF who report
moderate depression or moderate-to-severe anxiety, antidepres-
sant medication should be considered when psychological inter-
ventions are not feasible or fully effective (see ﬁgures 2 and 3).
See Recommendations 11, 12 and 13 in table 1.
When pharmacotherapy is needed, the selective serotonin
reuptake inhibitors (SSRIs) citalopram, escitalopram, sertraline
Figure 1 A ﬂexible, stepped-care model for assessing and treating depression and anxiety.
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Figure 2 Screening and treatment of depression and anxiety: algorithm for individuals with cystic ﬁbrosis (CF) (ages 12–adulthood). CBT, cognitive
behavioural therapy; GAD-7, Generalised Anxiety Disorder 7-item Scale; IPT, interpersonal therapy; PHQ-9, Patient Health Questionnaire 9; SSRI,
selective serotonin reuptake inhibitor.
Figure 3 Screening and treatment of depression and anxiety: algorithm for parents/caregivers. CBT, cognitive behavioural therapy; GAD-7,
Generalised Anxiety Disorder 7-item Scale; IPT, interpersonal therapy; PHQ-9, Patient Health Questionnaire 9.
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and ﬂuoxetine are appropriate initial choices for most adoles-
cents and adults with CF (see online supplementary appendix D
and table 4). The ICMH sought to identify a short list of medi-
cations with strong evidence for their use in medical popula-
tions. SSRIs, although commonly referred to as antidepressants,
are recommended by virtually all published guidelines as ﬁrst-
line medications for both depression and anxiety. Given the fre-
quent co-occurrence of depression and anxiety in CF,13 the
effectiveness of SSRIs in treating either condition or both simul-
taneously is advantageous; this has not been demonstrated for
many alternative antidepressants or antianxiety agents. Among
the SSRIs and alternative agents, citalopram, escitalopram, ser-
traline and ﬂuoxetine are more likely to be available inexpen-
sively in many countries, covered by health plans, have
regulatory approvals in a variety of age groups and minimise the
potential for medication interactions and side effects. See
Recommendation 14 in table 1.
Since the pharmacokinetics of medications may be altered in
CF and may be variable across individuals, optimal dose adjust-
ment of psychopharmacological agents requires close monitor-
ing of therapeutic beneﬁts, adverse effects and medical status. In
CF, pulmonary, gastrointestinal/hepatic, renal and nutritional
changes are particularly salient. Dose reduction may be required
in individuals with renal or hepatic impairment,
treatment-emergent adverse effects or drug–drug interactions.
Dose increases may be required for those with impaired absorp-
tion or enhanced hepatic metabolism, partial response to treat-
ment or drug–drug interactions. Therapeutic drug monitoring
of blood levels, when available, may supplement clinical moni-
toring of psychotropic medication dosing. See Recommendation
14 in table 1.
To reduce the risk of drug–drug interactions, prescribing clini-
cians should be informed of all medications used daily, regularly
cycled or used periodically for CF exacerbations. For example,
when used with lumacaftor, the doses of citalopram, escitalo-
pram and sertraline may need to be increased. Linezolid is not
recommended for use with serotonergic antidepressants when
alternatives are readily available. When both are clinically neces-
sary, the lowest effective doses should be used, with informed
consent and monitoring for serotonin syndrome. QTc prolonga-
tion, while not usually clinically signiﬁcant, is more likely with
citalopram than other SSRIs; electrocardiogram (EKG) and elec-
trolyte monitoring can be considered when simultaneous use of
multiple medications known to prolong the QTc is clinically
necessary.37
Anxiety in relation to medical procedures
For moderate-to-severe episodic anxiety associated with medical
procedures that have not responded to behavioural approaches,
the benzodiazepine lorazepam may be considered for short-term
use. Benzodiazepines require additional caution and monitoring
for those with a history of substance abuse, depression or an ele-
vated risk for respiratory depression, and local practice patterns
differ regarding their use to treat anxiety. Benzodiazepines are
preferable to SSRIs primarily when rapid onset of action is
needed or when serotonergic agents are contraindicated.
Lorazepam is available in both oral and intravenous forms, and
its duration of action is short enough to avoid a prolonged
period of sedation following a procedure. It is renally excreted
with no hepatic metabolism, which reduces medication interac-
tions and may be useful in the context of CF liver disease.
However, dose reduction may be necessary in patients who
develop renal insufﬁciency. See Recommendation 15 in table 1.
Medications used for treatment-resistant depression or
anxiety, which may carry increased risks of drug–drug interac-
tions and adverse effects in individuals with CF, are outside the
scope of this guideline. When necessary, they should be pre-
scribed and monitored by a psychiatric specialist in close collab-
oration with the CF team. Specialised consultation should also
be obtained when the psychiatric diagnosis is uncertain, the
complexity of the case exceeds the CF team’s level of training
and experience or when an urgent safety risk is identiﬁed.
RECOMMENDATIONS FOR IMPLEMENTATION AND FUTURE
RESEARCH
As screening for depression and anxiety is implemented in CF
centres internationally, the process of dissemination, implemen-
tation and resource provision should be closely monitored to
address barriers and concerns. As many international healthcare
providers do not have a colleague trained in mental health,22
implementation will require providing CF healthcare profes-
sionals with (1) training, easy access to resources and a ‘toolkit’
to facilitate implementation of annual mental health screening
(see online supplementary appendix D); (2) training in the pro-
vision of preventive and supportive interventions and (3) devel-
opment of referral networks within the hospital and community
for subsequent psychological and/or pharmacological manage-
ment of clinically diagnosed depression and anxiety. Many
initiatives directly tied to these recommendations are in process.
For example, the CFF in the USA recently convened a Task
Force on Mental Health, which outlined both the challenges
and the importance of implementing these new guidelines, is
sponsoring short courses and conference sessions on this topic
at the North American CF Conference and is launching a
‘request for applications’ to provide resources to CF centres that
implement screening and treatment. Addressing mental health
issues systematically is likely to improve health outcomes,
quality of life and reduce healthcare utilisation.10 38
Despite evidence in the TIDES study13 that a new diagnosis
of CF-related diabetes, and events such as haemoptysis and
pneumothorax, may precede elevations in symptoms of depres-
sion and anxiety, little is also known about the ‘triggers’ of psy-
chological symptoms, or how mood affects health outcomes in
this complex disease. The development of preventative strategies
will be enhanced by research which identiﬁes psychosocial and
clinical risk factors, such as maladaptive coping, social isolation,
CF clinical complications, markers of inﬂammation or vitamin
deﬁciencies that predict the onset of depression or anxiety in
individuals with CF. Large-scale studies are also required to
examine how psychological symptoms affect disease manage-
ment (eg, adherence) and health outcomes. In terms of cutting
edge questions, new evidence in other chronic conditions (eg,
cardiovascular disease) indicates that depression, independent of
disease state, can increase inﬂammation and lead directly to a
worsening of disease.39 New studies in CF are actively testing
this hypothesis, which if supported, adds urgency to the initi-
ation of both screening and treatment.
Although psychotherapy and medication treatments for
depression and anxiety are already used in CF,13 14 these inter-
ventions require further systematic research to inform future
recommendations. A recent Cochrane Review of psychological
treatments for individuals with CF found no controlled studies
evaluating interventions that address depression and anxiety in
either individuals with CF or parent caregivers.30 Randomised,
comparative effectiveness studies of psychotherapeutic and psy-
chopharmacological interventions for depression and anxiety in
CF are recommended. Additional studies are needed to
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understand not only the efﬁcacy of cognitive behavioural inter-
ventions, but also the pharmacokinetics, the frequency of gastro-
intestinal or pulmonary side effects or beneﬁcial weight gain. To
understand the full potential of psychological and pharmaco-
logical treatments to improve care, beyond the reduction of
symptoms of depression and anxiety, studies evaluating changes
in adherence to CF treatments and/or medical outcomes, as well
as the indirect effects of mental health treatment on parental
caregivers, should be investigated. Multicentre studies are
recommended to increase sample sizes and enhance statistical
power in trials of a rare condition, such as CF.
Finally, the inclusion of screening data, as well as intervention
efforts, in our national registries will greatly facilitate answers to
such pressing questions, including (1) evaluation of the preva-
lence of psychological symptoms by age, gender and disease
severity, (2) identiﬁcation of the predictors of elevated symp-
toms, (3) outcomes of both the screening and intervention pro-
cesses, (4) consequences of psychological symptoms on
adherence and health outcomes and (5) impact of psychological
distress on healthcare utilisation and cost. Novel forms of
service delivery, such as integrated care models or internet-based
education and treatment, are also worthy of investigation.40 41
CONCLUSION
Robust evidence indicates that adolescents, adults with CF and
parent caregivers report elevations in depression and anxiety
that should be identiﬁed and treated. Data also suggest that
these symptoms affect both disease management and health out-
comes. Systematic screening of these symptoms, with appropri-
ate intervention, offers the opportunity to signiﬁcantly improve
the quality of life and health of individuals with CF and their
parent caregivers.
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